Early Markers Of Neurodegeneration Laboratory – Prof. Anat Mirelman >>

Laboratory for Early Markers Of Neurodegeneration‎

arrow

Our Vision

Our mission is to better understand the pathological process of ageing and neurological diseases and discover new markers of neurodegeneration. We explore clinical, biological and neuronal markers using different tools such as neural-imaging (e.g., MRI, fMRI, EEG and fNIRS) and body fixed sensors with the aim of identifying sensitive measures that can quantify progression and predict neurodegeneration in prodromal and healthy individuals and populations at risk due of genetic mutations.

arrow

Contact Us

Primary Investigators
anat-m 921

Prof. Anat Mirelman, Lab PI

Phone: +972-3-6973014 / 3960
Email: Lemon@tlvmc.gov.il

favicon

Ora Assais, Lab administrative manager

Phone: +972-3-6973014 / 3960
Email: Lemon@tlvmc.gov.il

Address

Rishonim building

‎5th floor‎ ‎6 weizmann st.‎, Tel Aviv

arrow

Research

BeaT-PD

Collaborative project with Biogen aiming to identify prodromal markers of Parkinson’s disease. The study included healthy LRRK2 and GBA mutation carriers, who are individuals at risk for developing Parkinson’s disease. The longitudinal study explored clinical, biological, imaging and digital data

Parkinson Progressive Marker Initiative (PPMI)

PPMI is a landmark multi-site study collaborating with partners around the world to create a robust open-access data set and biosample library to speed scientific breakthroughs and new treatments. The study was initiated and funded by Michael J Fox Foundation.  

As part of PPMI, Prof. Mirelman leads the digital mobility efforts, exploring the potential and sensitivity of these technologies in identifying early disease.

Sleep monitoring at home using wearable technology

Sleep-related symptoms are one of the most common non-motor symptoms in Parkinson’s disease (PD). They have been associated with increased risk of neurodegeneration, cognitive decline, and reduced quality of life.  In this study, we are using novel wireless skin electrodes and wearable sensors to provide a “home-based sleep lab test”. The novel electrodes are printed on a thin and soft sticker, and are placed conveniently on the face of the person to enable  physiologic recordings (EEG, EOG, EMG) over multiple nights in the home environment. The study aims to evaluate the frequency and severity of sleep abnormalities in patients with PD. The study is funded by the US Department of Defense.

EEG and fNIRS for evaluating neural activation during function

Traditional neuroimaging is limited as it is done while the person is lying down, motionless in the scanner. In recent years, developments in imaging techniques such as Electroenchepalogram (EEG) and Functional Near-Infrared Spectroscopy (fNIRS) have paved the way to explore neural function and activation during actual performance.  Using these techniques we aim to understand neural dysfunction in different diseases and compensation activation in the face of disease. 

Motor-Cognitive Reserve

Postoperative cognitive dysfunction (POCD) and delirium, are unfortunately common, affecting 1.5–54.9% of surgical patients. A recent consensus statement defined postoperative Neuro Cognitive Decline (NCD) as a spectrum ranging from delirium, delayed neurocognitive recovery and POCD. The exact pathophysiology of neurocognitive dysfunction is not clear. This presents a challenge in identifying risk subjects for POCD. In this study we evaluate the predictive value of a novel motor-cognitive test in predicting delirium. This study is a collaborative project with the Surgical, Anestesia and critical care units.

arrow

Our Team

Current Staff

Researchers

Doctoral Student

MSc Student

Past Staff

Current funding

arrow

Highlighted Publications

Using Technology to Reshape Clinical Care and Research in Parkinson’s Disease. J Parkinsons Dis. Mirelman A, Dorsey ER, Brundin P, Bloem BR

2021;11(s1):S1-S3. doi: 10.3233/JPD-219002. PMID: 33612498.

Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. J Parkinsons Dis.

Thaler A, Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Shirvan JC, Cedarbaum JM, Orr-Urtreger A, Regev K, Shenhar- Tsarfaty S, Mirelman A

2021;11(3):1285-1296. doi: 10.3233/JPD-212624. PMID: 33998549; PMCID: PMC8461659.

Biochemical markers for severity and risk in GBA and LRRK2 Parkinson’s disease.

Thaler A, Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Cedarbaum JM, Orr-Urtreger A, Shenhar-Tsarfaty S, Mirelman A.

J Neurol. 2021 Apr;268(4):1517-1525. doi: 10.1007/s00415-020-10325-4. Epub 2021. Jan 3. PMID: 33388928

More Publications >>

A multimodal approach using TMS and EEG reveals neurophysiological changes in Parkinson’s disease.

Maidan I, Zifman N, Hausdorff JM, Giladi N, Levy-Lamdan O, Mirelman A.

Parkinsonism Relat Disord. 2021;89:28-33.

Whole brain and deep gray matter structure segmentation: Quantitative comparison between MPRAGE and MP2RAGE sequences . Droby A, Thaler A, Giladi N, Hutchison RM, Mirelman A, Ben Bashat D, Artzi M. PLoS One. 2021 Aug 6; 16(8):e0254597. doi: 10.1371/ journal.pone.0254597. PMID: 34358242; PMCID: PMC8345829.

Detecting Sensitive Mobility Features for Parkinson’s disease stages via Machine learning

Mirelman A, Ben Or Frank M, Melamed M, Granovsky L, Nieuwboer A, Rochester L, Del Din S, Avanzino L, Pelosin E, Bloem BR, Della Croce U, Cereatti A, Bonato P, Camicioli R, Ellis T, Hamilton JL, Hass CJ, Almeida QJ, Inbal M, Thaler A, Shirvan J, Cedarbaum JM, Giladi N, Hausdorff JM.

Mov Disord. 2021

Quantitative digital clock drawing test as a sensitive tool to detect subtle cognitive impairments in early stage Parkinson’s disease

Schejter-Margalit T, Kizony R, Shirvan J, Cedarbaum JM, Bregman N, Thaler A, Giladi N, Mirelman A.

Parkinson and  Relat Disord. 2021

Gait and cognitive abnormalities are associated with regional cerebellar atrophy in elderly fallers- a pilot study

Droby A, El Mendili MM, Giladi N, Hausdorff JM, Maidan I, Mirelman A.

Gait Posture. 2021

Whole brain and deep gray matter structure segmentation: Quantitative comparison between MPRAGE and MP2RAGE sequences . Droby A, Thaler A, Giladi N, Hutchison RM, Mirelman A, Ben Bashat D, Artzi M. PLoS One. 2021 Aug 6; 16(8):e0254597. doi: 10.1371/ journal.pone.0254597. PMID: 34358242; PMCID: PMC8345829.

Neural variability in the prefrontal cortex as a reflection of neural flexibility in patients with Parkinson’s disease

Maidan I, Hacham R, Galperin I, Giladi N, Holtzer R, Hausdorff JM, Mirelman

Neurology. 2021

Glucocerebrosidase activity in not associated with Parkinson;s disease risk or severity

Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein

O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A.

Mov Disord. 2022

Event-related oscillations differentiate between cognitive, motor and visual impairments

Rosenblum Y, Shiner T, Bregman N, Fahoum F, Giladi N, Maidan I, Mirelman A.

J Neurol. 2022

Less Publications >>

arrow-w

From The Press